EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluating an anti-idiotype derived germline-targeting immunogen designed to elicit VRC01-class precursors in human antibody transgenic mice

Crystal B Chhan iD, Yu-Hsin Wan, Andrew Wilcox-King, Leah J Homad, Nicholas T Aldridge, Roman Iureniev, Leonidas Stamatatos iD, Andrew T McGuire iD

mSphere · 29.09.2026 · 11 (9)

DOI: 10.1128/msphere.00317-26 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mSphere, erschienen am 29.09.2026. Verfasst von Crystal B Chhan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA. Hauptthemen laut MEDLINE: HIV Antibodies, Antibodies, Monoclonal, Antibodies, Anti-Idiotypic, AIDS Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NCI NIH HHS, National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An effective HIV-1 vaccine will likely need to elicit broadly neutralizing antibodies (bNAbs) that bind relatively conserved regions of the otherwise highly variable envelope glycoprotein. Among these, VRC01-class bNAbs are a reproducible antibody class that bind the CD4-binding site through genetic features encoded by the VH1-2 heavy chain and a light chain containing a rare five-amino-acid-long complementarity-determining region 3 (CDRL3). We previously developed a germline-targeting immunogen, iv4/iv9, derived from anti-idiotypic monoclonal antibodies (ai-mAbs) that target these genetic signatures of VRC01-class bNAbs. Here, we applied structure-guided modification of iv4/iv9 that improved selective binding to VRC01 precursors in vitro and carried out immunizations in ATX-GK mice. These mice are transgenic for human antibody genes, producing a diverse, genetically human antibody repertoire. We found that ATX-GK mice harbor VRC01 precursors at frequencies lower than those found in humans. Class-switched VRC01 precursors were detected in a minority of mice immunized with a modified iv4/iv9 immunogen. Collectively, these results indicate that the ATX-GK mice have utility to evaluate VRC01-class germline-targeting immunogens but are a stringent model due to a low frequency of VRC01-class B cells. They further suggest that the ai-mAb immunogens evaluated herein will require further optimization to reproducibly prime VRC01-class B cells in ATX-GK mice. IMPORTANCE An effective HIV-1 vaccine will likely need to elicit broadly neutralizing antibodies (bNAbs) that bind relatively conserved regions of the otherwise highly variable envelope glycoprotein. Among these, VRC01-class bNAbs are a reproducible antibody class that bind the CD4-binding site through genetic features encoded by the VH1-2 heavy chain and a light chain containing a rare five-amino-acid-long complementarity-determining region 3 (CDRL3). We previously developed a germline-targeting immunogen, iv4/iv9, derived from anti-idiotypic monoclonal antibodies that target these genetic signatures of VRC01-class bNAbs. Here, we evaluate the B-cell response to immunization with iv4/iv9 and with a structure-guided modified iv4/iv9 in ATX-GK mice. These modifications are intended to improve the selectivity of VRC01 precursors in a diverse polyclonal B cell repertoire. These mice are transgenic for human antibody genes, producing a diverse, genetically human antibody repertoire. We found that ATX-GK mice harbor VRC01 precursors at frequencies lower than those found in humans. Class-switched VRC01 precursors were detected in a minority of animals immunized with the modified iv4/iv9. Collectively, these results indicate that although the iv4/iv9 immunogen did not reproducibly elicit VRC01-class B cells, ATX-GK mice have utility to evaluate VRC01-class germline-targeting immunogens but are a stringent model due to a low frequency of VRC01-class B cells.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV AntibodiesAntibodies, MonoclonalAntibodies, Anti-IdiotypicAIDS VaccinesBroadly Neutralizing AntibodiesAnimalsHumansMice, TransgenicMiceHIV-1Antibodies, NeutralizingFemale

Stichwörter der Autor:innen

HIV-1anti-idiotypeantibodiesgermline targetingtransgenic mice

Substanzen

HIV AntibodiesAntibodies, MonoclonalAntibodies, Anti-IdiotypicVRC01 monoclonal antibodyAIDS VaccinesBroadly Neutralizing AntibodiesAntibodies, Neutralizing

Autor:innen und Institutionen

  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.
  • Department of Global Health, University of Washington, Seattle, Washington, USA.
  • Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.

ORCID-Profile: Crystal B Chhan, Leonidas Stamatatos, Andrew T McGuire

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Chhan, C. B., Wan, Y. H., Wilcox-King, A., Homad, L. J., Aldridge, N. T., Iureniev, R., Stamatatos, L., & McGuire, A. T. (2026). Evaluating an anti-idiotype derived germline-targeting immunogen designed to elicit VRC01-class precursors in human antibody transgenic mice. mSphere, 11(9). https://doi.org/10.1128/msphere.00317-26

Vancouver

Chhan CB, Wan YH, Wilcox-King A, Homad LJ, Aldridge NT, Iureniev R, et al. Evaluating an anti-idiotype derived germline-targeting immunogen designed to elicit VRC01-class precursors in human antibody transgenic mice. mSphere. 2026;11(9). doi:10.1128/msphere.00317-26

BibTeX
@article{Chhan2026,
  author = {Chhan, Crystal B and Wan, Yu-Hsin and Wilcox-King, Andrew and Homad, Leah J and Aldridge, Nicholas T and Iureniev, Roman and Stamatatos, Leonidas and McGuire, Andrew T},
  title = {Evaluating an anti-idiotype derived germline-targeting immunogen designed to elicit VRC01-class precursors in human antibody transgenic mice},
  journal = {mSphere},
  year = {2026},
  volume = {11},
  number = {9},
  doi = {10.1128/msphere.00317-26}
}
Kostenlos starten →